The secretome of senescent monocytes predicts age-related clinical outcomes in humans.
Abstract
Cellular senescence increases with age and contributes to age-related declines and pathologies. We identified circulating biomarkers of senescence and related them to clinical traits in humans to facilitate future noninvasive assessment of individual senescence burden, and efficacy testing of novel senotherapeutics. Using a nanoparticle-based proteomic workflow, we profiled the senescence-associated secretory phenotype (SASP) in THP-1 monocytes and examined these proteins in 1,060 plasma samples from the Baltimore Longitudinal Study of Aging. Machine-learning models trained on THP-1 monocyte SASP associated SASP signatures with several age-related phenotypes in a test cohort, including body fat composition, blood lipids, inflammatory markers and mobility-related traits, among others. Notably, a subset of SASP-based predictions, including a high-impact SASP panel, were validated in InCHIANTI, an independent aging cohort. These results demonstrate the clinical relevance of the circulating SASP and identify potential senescence biomarkers that could inform future clinical studies.
The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.
Research summary
The paper claims that circulating biomarkers of the senescence-associated secretory phenotype (SASP) can predict age-related clinical outcomes in humans. This research is relevant as it addresses cellular senescence, a fundamental mechanism of aging, and seeks to identify biomarkers that could lead to noninvasive assessments of senescence burden, potentially informing interventions that target the root causes of aging.
Author of this paper? Send a correction.